Skip to content

Identification of neutralizing antibodies against severe or chronic infections of human being

Identification of neutralizing antibodies against severe or chronic infections of human being - INA

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00010169
Enrollment
1000
Registered
2016-04-13
Start date
2016-08-28
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients suffering from chronic infections or passing trough server infections within the last 10 years

Interventions

Group 1: blood withdrawal or apherese of patients who either have overcome severe infections or those natural immune system are able to control chronic infections stably Group 2: blood withdrawal or a

Sponsors

Universitätsklinikum Köln
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients suffering from chronic infections or passing trough severe infections within the last 10 years or healthy people as volunteers, and Karnofsky > 80

Exclusion criteria

Exclusion criteria: - Leukopenia 250 mL, a body weight of 50 kg is required) - 100 mL - Within 1 week after small surgery (biopsy, tooth extraction), or within 1 month after larger surgery (e.g., thoracotomoy, open abdominal surgery) or surgery with high risk of postoperative bleeding (e.g., tonsillectomy) - Acute or unknown health deterioration - Participation in another interventional study If a leukapheresis is planned, the following additional exclusion criteria apply: - History of significant complication from leukapheresis or citrate-based anticoagulation - INR > 1.5 or aPTT > 60 s - Premenopausal women that cannot rule out pregnancy at the time of apheresis

Design outcomes

Primary

MeasureTime frame
Identification of neutralizing antibodies. Following methods are used: 1. isolation of B cells via flow cytometry ; 2. gene sequencing of antigen-coding central regions; 3. cloning and expression of identified genes; 4. functional analysis of rebuild antibodies using binding studies (ELISA, Biacore) and neutralization testings

Countries

Germany

Contacts

Public ContactHenning Grüll

Institut für Virologie – Uniklinik Köln

henning.gruell@uk-koeln.de+49 221 478 96973

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026